MarketPulse
Q

$QURE

66 articles found
1 positive
65 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

uniQure Faces Securities Lawsuit Over Pivotal Study Misrepresentations

uniQure faces securities class action lawsuit alleging misstatements about Pivotal Study design and FDA approval. Lead plaintiff deadline: April 13, 2026.
LAKEQUREPSFEsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Claimsfiler

Gene Therapy Stock $QURE Crashes 49% as FDA Rejects AMT-130 Data; Class Action Looms

$QURE plunged 49% after FDA rejected AMT-130 Phase I/II data for accelerated approval. Securities lawsuit filed; lead plaintiff deadline April 13, 2026.
QUREsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Paysafe Investors Face April Deadline in Securities Class Action Over Alleged Disclosure Failures

Rosen Law Firm urges Paysafe investors to join securities class action alleging disclosure failures, with April 7, 2026 lead plaintiff deadline.
LAKEQUREPSFEsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

uniQure Stock Crashes 49% After FDA Rejects Gene Therapy Data

uniQure stock plunges 49% after FDA rejects gene therapy data for AMT-130, triggering securities fraud class action lawsuit for investors trading September-October 2025.
QUREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Block & Leviton Llp

Driven Brands Under Fire: Securities Fraud Investigation Launched After 35% Stock Plunge

Driven Brands under SEC investigation for securities fraud after disclosing material accounting errors, overstated cash and revenue, causing stock to fall 35%.
QUREEOSEDRVNsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kessler Topaz Meltzer & Check, Llp

uniQure Stock Crashes 49% as FDA Rejects Huntington's Gene Therapy Pathway

uniQure's $QURE stock crashes 49% after FDA rejects Huntington's gene therapy approval pathway; securities fraud lawsuit filed alleging misleading statements about regulatory expectations.
QUREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

uniQure Faces Securities Lawsuit Over FDA Study Design Misrepresentations

uniQure faces securities class action over alleged misrepresentations regarding FDA approval status of Huntington's Disease trial design and regulatory timeline delays. Lead plaintiff deadline April 13, 2026.
QUREsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

UniQure Investors Urged to Consult Legal Counsel Ahead of Securities Suit Deadline

UniQure faces securities lawsuit alleging material misrepresentations about its Huntington's Disease trial design and FDA approval status. Lead plaintiff deadline is April 13, 2026.
QUREsecurities class actionFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Claimsfiler

uniQure Class Action: Deadline Set for Lead Plaintiff Claims Over FDA Disclosure

uniQure faces class action lawsuit over failing to disclose FDA rejection of AMT-130 drug candidate, causing 49% stock decline. Lead plaintiff deadline: April 13, 2026.
QUREsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Legal Action Filed Against uniQure Over FDA Approval Statements

Class action lawsuit filed against uniQure for allegedly making false statements about FDA approval status and BLA submission timelines, misleading investors.
QUREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

uniQure Faces Securities Fraud Lawsuit Following FDA Rejection, 49% Stock Plunge

uniQure faces securities fraud lawsuit after FDA rejected its drug candidate AMT-130, causing a 49% stock plunge. Plaintiffs allege the company failed to disclose material information to investors.
CORTBRBRQUREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

Corcept Therapeutics Faces Securities Fraud Lawsuit Over Undisclosed FDA Setback

Corcept Therapeutics faces securities fraud lawsuit for failing to disclose FDA setback on relacorilant drug, causing 50% stock decline.
CORTBRBRQUREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

Law Firm Files Securities Fraud Claims Against BellRing After 52% Stock Plunge

Law firm files securities fraud lawsuit against BellRing after 52% stock plunge, alleging failure to disclose inventory and supply chain issues.
CORTBRBRQUREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

uniQure Faces Class Action Over FDA Study Claims and BLA Timeline Disclosures

uniQure faces class action lawsuit alleging misleading statements about FDA study status and BLA timeline delays. Investors who purchased shares Sept-Oct 2025 may be eligible to claim.
QUREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Class Action Deadline Looms for uniQure Investors Amid FDA Approval Claims

uniQure faces securities class action over allegedly misleading FDA approval claims and timeline delays. Investors must act before April 13, 2026 deadline.
QUREVTGNLUinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Class Action Lawsuit Filed Against uniQure Over Alleged Regulatory Misstatements

Securities fraud lawsuit filed against uniQure for allegedly making false statements about FDA approval processes and BLA submission timelines, causing investor losses.
QUREsecurities fraudclass action lawsuit
BenzingaBenzinga··Prnewswire

uniQure Securities Class Action Seeks Investors Over FDA Approval Claims

uniQure faces securities class action lawsuit over allegedly false FDA approval statements. Investors who purchased stock between September-October 2025 can join the case by April 2026.
QUREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kirby Mcinerney Llp

Class Action Lawsuit Alleges uniQure Withheld FDA Study Design Concerns

Class action lawsuit alleges uniQure withheld FDA study design concerns from investors, causing 49% stock decline after disclosure in November 2025.
QUREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Class Action Lawsuit Filed Against uniQure Over FDA Approval Disclosures

uniQure faces class action lawsuit alleging misleading FDA approval statements and understated BLA timeline risks. Investors who purchased securities between September-October 2025 may be eligible to participate.
QUREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Claimsfiler

uniQure Faces Securities Lawsuit Over FDA Disclosure Gap; Lead Plaintiff Deadline Set

uniQure faces securities lawsuit over failing to disclose that FDA rejected its gene therapy candidate AMT-130, causing stock to plunge 49%. Lead plaintiff deadline set for April 13, 2026.
QUREsecurities class actionlead plaintiff deadline